Pre-market Hot Trades in US Stocks
Elevance Health is up 3.04% in pre-market trading. Based on recent important news:
<ol>
<li>
On September 8, Elevance Health submitted pricing terms for a four-part note issuance of up to $3 billion, driving the stock price up. This move indicates positive progress in the company's financing plans, enhancing market confidence. Data source: SEC filings.
</li>
<li>
On September 10, institutional investors took a bullish stance on Elevance Health, reflected in the historical options trading, showing signs of capital inflow. This indicates market optimism regarding the company's long-term prospects. Data source: Benzinga.
</li>
<li>
On September 10, analysts generally rated Elevance Health as &#34;Buy,&#34; with a target price of $355, representing a potential upside of 14.59% from current levels. This rating reinforces the market's positive expectations for the stock. Data source: TipRanks. Defensive capital inflow in the healthcare sector is significant.
</li>
</ol>
Top Gainers in Pre-market Trading of US Stocks
Silexion Therapeutics is up 232.66% in pre-market trading. Based on recent important news:
<ol>
<li>
On September 11, Silexion Therapeutics announced that its experimental therapy SIL20 successfully reached major sites of pancreatic cancer metastasis, including the liver, peritoneum, and lungs, significantly reducing tumor burden in preclinical studies. This news drove the stock price up 241.4%. Data source: Company announcement.
</li>
<li>
On September 11, technical analysis showed a bearish trend in the stock price, but the company's positive preclinical results and collaboration with SIL204 provide potential upside. Data source: Technical analysis report.
</li>
<li>
On September 11, Silexion Therapeutics plans to make regulatory submissions in Q4 2025 and Q1 2026, and to initiate Phase 2/3 clinical trials in the first half of 2026. This plan further enhances market confidence. Data source: Company announcement. The biotechnology sector has shown strong recent performance, with significant capital inflow.
</li>
</ol>
Vince Holding is up 164.46% in pre-market trading. Based on recent important news:
<ol>
<li>
On September 10, Vince Holding announced its Q2 financial report, with net income of $12.06 million and earnings per share of $0.93, exceeding market expectations and driving the stock price significantly higher. Data source: Company financial report.
</li>
<li>
On September 10, Vince Holding's management forecasted that net sales for Q3 will be flat or grow by 3%, and plans to offset some tariff costs through new procurement and price adjustments, enhancing market confidence. Data source: Company outlook.
</li>
<li>
On September 10, analysts rated Vince Holding as &#34;Buy,&#34; with a target price of $3.25, 48.9% higher than the last closing price, further boosting investor sentiment. Data source: Analyst report
The overall performance of the clothing industry is stable, and attention should be paid to the impact of tariffs
</li>
</ol>

Elevance Health rose 3.04% in pre-market; Silexion Therapeutics rose 232.66% in pre-market; Vince Holdings rose 164.46% in pre-market; YY rose 90.30% in pre-market

Pre-market hot trades in US stocks: Elevance Health up 3.04% in pre-market